Bcl-2 blocks 2-methoxyestradiol induced leukemia cell apoptosis by a p27Kip1-dependent G1/S cell cycle arrest in conjunction with NF-κB activation

Biochemical Pharmacology

Volumn 78, Issue 1, 2009, Pages 33-44

  Batsi, Christina ^a   Markopoulou, Soultana ^a   Kontargiris, Evangelos ^a   Charalambous, Christiana ^b   Thomas, Christoforos ^a   Christoforidis, Savvas ^c,d   Kanavaros, Panagiotis ^e   Constantinou, Andreas I ^b   Marcu, Kenneth B ^f,g   Kolettas, Evangelos ^a,d  

^a Clinic of Social and Family Medicine   (Greece)

^b UNIVERSITY OF CYPRUS   (Cyprus)

^c UNIVERSITY OF IOANNINA   (Greece)

^d INSTITUTE OF COMPUTER SCIENCE   (Greece)

^e School of Medicine   (Greece)

^f STONY BROOK UNIVERSITY   (United States)

^g UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

2 Methoxyestradiol (2 ME2); Apoptosis; Bcl 2; Cell cycle; NF B; p27Kip1

Indexed keywords

2 METHOXYESTRADIOL; CASPASE 3; CASPASE 9; CYCLIN D3; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN E; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN BAK; PROTEIN BCL 2; RETROVIRUS VECTOR; TRANSCRIPTION FACTOR E2F1;

AGAR GEL ELECTROPHORESIS; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FRAGMENTATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

APOPTOSIS; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; ESTRADIOL; G1 PHASE; HUMANS; JURKAT CELLS; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-BCL-2; S PHASE;

EID: 67349208974     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.03.017     Document Type: Article

References (82)

1. Fotsis T., Zhang Y., Pepper M.S., Adlercreutz H., Montesano R., Nawroth P.P., et al. The endogenous estrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368 (1994) 237-239
2. D'Amato R.J., Lin C.M., Flynn E., Folkman J., and Hamel E. 2-methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci USA 91 (1994) 3964-3968
3. Klauber N., Parangi S., Flynn E., Hamel E., and D'Amato R.J. Inhibition of angiogenesis and breast cancer in mice by microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 57 (1997) 81-86
4. Pribluda V.S., Gubish Jr. E.R., LaVallee T.M., Treston A., Swartz G.M., and Green S.J. 2-methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev 19 (2000) 173-179
5. Ryoo J.J., Cole C.E., and Anderson K.C. Novel therapies for multiple myeloma. Blood Rev 16 (2002) 167-174
6. Lakhani N.J., Sarkar M.A., Venitz J., and Figg W.D. 2-methoxyestradiol, a promising anticancer agent. Pharmacotherapy 23 (2003) 165-172
7. Mooberry S.L. New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent. Curr Opin Oncol 15 (2003) 425-430
8. Mooberry S.L. Mechanism of action of 2-methoxyestradiol: new developments. Drug Resist Update 6 (2003) 355-361
9. Attalla H., Mäkelä T.P., Adlercreutz H., and Anderson L.C. 2-methoxyestradiol arrests cells in mitosis without depolymerising tubulin. Biochem Biophys Res Commun 228 (1996) 467-473
10. Dingli D., Timm M., Russell S.J., Witzig T.E., and Rajkumar S.V. Promising preclinical activity of 2-methoxyestradiol in multiple myeloma. Clin Cancer Res 8 (2002) 3948-3954
11. cdc2 and cyclin B1 expression. Int J Oncol 15 (1999) 639-646
12. La Vallee T.M., Zhan X.H., Herbstritt C.J., Kough F.C., Green S.J., and Pribluda V.S. 2-methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors α and β. Cancer Res 62 (2002) 3691-3697
13. Kumar A.P., Garcia G.E., and Slaga T.J. 2-methoxyestradiol blocks cell cycle progression at G2/M phase and inhibits growth of human prostate cancer cells. Mol Carcinogen 31 (2001) 111-124
14. Qadan L.R., Perez-Stable C.M., Abderson C., D'Ippolito G., Herron A., Howard G.A., et al. 2-methoxystradiol induces G2/M arrest and apoptosis in prostate cancer. Biochem Biophys Res Commun 285 (2001) 1259-1266
15. Bu S., Blaukat A., Fu X., Heldin N.-E., and Landström M. Mechanisms for 2-methoxyestradiol-induced apoptosis of prostate cancer cells. FEBS Lett 531 (2002) 141-151
16. Lin H.L., Liu T.Y., Wu V.W., and Chi C.W. 2-methoxyestradiol-induced caspase-3 activation and apoptosis occurs through G2/M arrest dependent and independent pathways in gastric carcinoma cells. Cancer 92 (2001) 500-509
17. Ghosh R., Ott A.M., Seetharam D., Slaga T.J., and Kumar A.P. Cell cycle block and apoptosis induction in a human melanoma cell line following treatment with 2-methoxyestradiol: therapeutic implications. Melanoma Res 13 (2004) 119-127
18. Kumar A.P., Garcia G.E., Orsborn J., Levin V.A., and Slaga T.J. 2-methoxyestradiol interferes with NF-κB transcriptional activity in primitive neuroectodermal brain tumors: implications for management. Mol Carcinogen 24 (2003) 209-216
19. Seegers J.C., Lottering M.L., Grobler C.J., van Papendorp D.H., Habbersett R.C., Shou Y., et al. The mammalian metabolite, 2-methoxyestradiol, affects p53 levels and apoptosis induction in transformed cells but not in normal cells. J Steroid Biochem Mol Biol 62 (1997) 253-267
20. Schumacher G., Kataoka M., Roth J.A., and Mukhopadhyay T. Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines. Clin Cancer Res 5 (1999) 493-499
21. Golebiewska J., Rozwadowski P., Spodnik J.H., Knap N., Wakabayashi Y., and Wozniak M. Dual effect of 2-methoxyestradiol on cell cycle events in human osteosarcoma 143b cells. Acta Biochim Pol 49 (2002) 59-65
22. Qanungo S., Basu A., Das M., and Haldar S. 2-methoxyestradiol induces mitochondrial dependent apoptotic signaling in pancreatic cancer cells. Oncogene 21 (2002) 4149-4157
23. Mukhopadhay T., and Roth J.A. Induction of apoptosis in human cancer cells after wild-type p53 activation by methoxyestradiol. Oncogene 14 (1997) 379-384
24. Chauhan D., Li G., Hideshima T., Podar K., Mitsiades C., Mitsiades N., et al. Superoxide-dependent and independent mitochondrial signalling during apoptosis in multiple myeloma. Oncogene 22 (2003) 6296-6300
25. Mabjeesh N.J., Escuin D., La Valle T.M., Pribluda V.S., Stewart G.M., Johnson M.S., et al. 2-ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3 (2003) 363-375
26. Gao N., Rahmani M., Dent P., and Grant S. 2-methoxyestradiol-induced apoptosis in human leukaemia cells proceeds through a reactive oxygen species and Akt-dependent process. Oncogene 24 (2005) 3797-3809
27. 2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induction and apoptosis. Carcinogenesis 24 (2003) 1067-1075
28. Bu S.Z., Huang Q., Jiang Y.M., Min H.B., Hou Y., Guo Z.Y., et al. p38 Mitogen-activated protein kinases is required for counteraction of 2-methoxyestradiol to estradiol-stimulated cell proliferation and induction of apoptosis in ovarian carcinoma cells via phosphorylation Bcl-2. Apoptosis 11 (2006) 413-425
29. Attalla H., Westberg J.A., Andersson L.C., Adlercreutz H., and Mäkelä T.P. 2-methoxyestradiol-induced phosphorylation of Bcl-2: uncoupling from JNK/SAPK activation. Biochem Biophys Res Commun 247 (1998) 616-619
30. L phosphorylation site regulating the sensitivity of taxol- or 2-methoxyestradiol-induced apoptosis. FEBS Lett 538 (2003) 41-47
31. Hengartner M.O. The biochemistry of apoptosis. Nature 407 (2000) 770-776
32. Adams J.M., and Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26 (2007) 1324-1337
33. Chipuk J.E., and Green D.R. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?. Trends Cell Biol 18 (2008) 157-164
34. Verma Y.K., Gangenahalli G.U., Singh V.K., Gupta P., Chandra R., Sharma R.K., et al. Cell death regulation by B-cell lymphoma protein. Apoptosis 11 (2006) 459-471
35. Deng X., Kornblau S.M., Ruvolo P.P., and May Jr. W.S. Regulation of Bcl-2 phosphorylation and potential significance for leukemic cell chemoresistance. J Nat Cancer Inst Monogr 28 (2000) 30-37
36. Yamamoto K., Ichijo H., and Korsmeyer S.J. Bcl-2 is phosphorylated and inactivated by ASK1/jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 19 (1999) 8469-8478
37. Srivastava R.K., Mi Q.S., Hardwick J.M., and Longo D.L. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci USA 96 (1999) 3775-3780
38. Haldar S., Chintapalli J., and Croce C.M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56 (1996) 1253-1255
39. Pathan N., Aime-Sempe C., Kitada S., Basu A., Haldar S., and Reed J.C. Microtubule-targeting drugs induce Bcl-2 phosphorylation and association with Pin1. Neoplasia 3 (2001) 550-559
40. Huang P., Feng L., Oldham A., Keating M.J., and Plunkett W. Superoxide dismutase as a target for killing of cancer cells. Nature 407 (2000) 390-395
41. Tang D., Okada H., Ruland J., Liu L., Stambolic V., Mak T.W., et al. Akt is activated in response to an apoptotic signal. J Biol Chem 276 (2001) 30461-30466
42. Kip1, expression by E2F1: a negative feedback mechanism. J Biol Chem 280 (2005) 12339-12343
43. Li J., Peet G.W., Balzarano D., Li X., Massa P., Barton R.W., et al. Novel NEMO/IκB kinase and NF-κB target genes at the pre-B to immature B cell transition. J Biol Chem 276 (2001) 18579-18590
44. Kolettas E., Skoufos I., Kontargiris E., Markopoulou S., Tzavaras Th, and Gonos E.S. Bcl-2 but not clusterin/apolipoprotein J protected human diploid fibroblasts and immortalised keratinocytes from ceramide-induced apoptosis: role of p53 in the ceramide response. Arch Biochem Biophys 445 (2006) 184-195
45. Dimri G.P., Hara E., and Campisi J. Regulation of two E2F-related genes in presenescent and senescent human fibroblasts. J Biol Chem 269 (1994) 16180-16186
46. Reddy K.B., Karode M.C., Harmony J.A.K., and Howe P.H. Transforming growth factor β (TGFβ)-induced nuclear localization of apolipoprotein J/clusterin in epithelial cells. Biochemistry 35 (1996) 6157-6163
47. Wang G.-Q., Gastman B.R., Wieckowski E., Goldstein L.A., Gambotto A., Kim T.-H., et al. A role for mitochondrial Bak in apoptotic response to anticancer drugs. J Biol Chem 276 (2001) 34307-34317
48. Wang G.-Q., Wieckowski E., Goldstein L.A., Gastman B.R., Rabinovitz A., Gambotto A., et al. Resistance to granzyme B-mediated cytochrome c release in Bak-deficient cells. J Exp Med 194 (2001) 1325-1337
49. Zinkel S., Gross A., and Yang E. BCL2 family in DNA damage and cell cycle control. Cell Death Differ 13 (2006) 1351-1359
50. Scheel-Toellner D., Raza K., Assi L., Pilling D., Ross E.J., Lee W.Y., et al. Differential regulation of nuclear and mitochondrial Bcl-2 in T cell apoptosis. Apoptosis 13 (2008) 109-117
51. Kaufmann J.A., Perez M., Zhang W.R., Bickford P.C., Holmes D.B., and Taglialatela G. Free radical-dependent nuclear localization of Bcl-2 in the central nervous system of aged rats is not associated with Bcl-2-mediated protection from apoptosis. J Neurochem 87 (2003) 981-994
52. Massaad C.A., Portier B.P., and Taglialatela G. Inhibition of transcription factor activity by nuclear compartment-associated Bcl-2. J Biol Chem 279 (2004) 54470-54478
53. Kip1, pRB relative p130 and altered E2F regulation. Mol Cell Biol 20 (2002) 4745-4753
54. Greider C., Chattopadhyay A., Parkhurst C., and Yang E. Bcl-XL and Bcl-2 delay myc-induced cell cycle entry through elevation of p27 and inhibition of G1 cyclin-dependent kinases. Oncogene 21 (2002) 7765-7775
55. Deng X., Gao F., and May Jr. W.S. Bcl2 retards G1/S cell cycle transition by regulating intracellular ROS. Blood 102 (2003) 3179-3185
56. Kip1 metabolism. Cell Cycle 6 (2007) 1053-1061
57. ADR breast cancer cells. Int J Cancer 86 (2000) 188-196
58. Jang J.-H., and Surh Y.-J. Bcl-2 attenuation of oxidative cell death is associated with up-regulation of γ-glutamylcysteine ligase via constitutive NF-κB activation. J Biol Chem 279 (2004) 38779-38786
59. Crawford M.J., Krishnamoorthy R.R., Rudick V.L., Collier R.J., Kapin M., Aggarwal B.B., et al. Bcl-2 overexpression protects photooxidative stress-induced apoptosis of photoreceptor cells via NF-κB preservation. Biochem Biophys Res Commun 281 (2001) 1304-1312
60. Albrecht H., Tschopp J., and Jongenel C.V. Bcl-2 protects from oxidative damage and apoptotic cell death without interfering with activation of NF-κB by TNF. FEBS Lett 351 (1994) 45-48
61. Herrmann J.L., Beham A.W., Sarkiss M., Chiao P.J., Rands M.T., Bruckheimer E.M., et al. Bcl-2 suppresses apoptosis resulting from disruption of the NF-κB survival pathway. Exp Cell Res 237 (1997) 101-109
62. Hammerman P.S., Fox C.J., Cinalli R.M., Xu A., Wagner J.D., Lindsten T., et al. Lymphocyte transformation by Pim-2 is dependent on nuclear factor-κB activation. Cancer Res 64 (2004) 8341-8348
63. kip1 gene promoter. FEBS Lett 411 (1997) 1-6
64. Cheng J., and Haas M. Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol 10 (1990) 5502-5509
65. Blagosklonny M.V., Bishop P.C., Robey R., Fojo T., and Bates S.E. Loss of cell cycle control allows selective microtubule-active drug-induced Bcl-2 phosphorylation and cytotoxicity in autonomous cancer cells. Cancer Res 60 (2000) 3425-3428
66. Deng X., Gao F., Flagg T., and May Jr. W.S. Mono- and multisite phosphorylation enhances Bcl2's antiapoptotic function and inhibition of cell cycle entry functions. Proc Natl Acad Sci USA 101 (2004) 153-158
67. Sicinska E., Aifantis I., Le Cam L., Swat W., Borowski C., Yu Q., et al. Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell 4 (2003) 451-461
68. Gladden A.B., and Diehl J.A. Cell cycle progression without cyclin E-CDK2: breaking down the walls of dogma. Cancer Cell 4 (2003) 160-162
69. Sherr C.J., and Roberts J.M. CDK inhibitors: positive and negative regulators of G1 phase progression. Genes Dev 13 (1999) 1501-1512
70. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment?. Trends Cell Biol 13 (2002) 65-70
71. - immature thymocytes. J Immunol 168 (2002) 2325-2331
72. INK4A interferes with Abelson virus transformation by enhancing apoptosis. J Virol 78 (2004) 3304-3311
73. Gartel A.L., and Tyner A.L. The role of cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 1 (2002) 639-649
74. Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 4 (2003) 425-429
75. O'Reilly L.A., Huang D.C.S., and Strasser A. The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J 15 (1996) 6979-6990
76. Borner C. Diminished cell proliferation associated with the death protective activity of bcl-2. J Biol Chem 271 (1996) 12695-12698
77. Huang D.C.S., O'Reilly L.A., Strasser A., and Cory S. The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J 16 (1997) 4628-4638
78. Johnson V.L., Cooper I.R., Jenkins J.R., and Chow S.C. Effects of differential overexpression of Bcl-2 on apoptosis, proliferation and telomerase activity in Jurkat cells. Exp Cell Res 251 (1999) 175-184
79. L/Bcl-2 coordinately regulate apoptosis, cell cycle arrest and cell cycle entry. EMBO J 22 (2003) 5459-5470
80. Cheng N., Janumyan Y.M., Didion L., van Holfwegen C., Yang E., and Knudson C.M. Bcl-2 inhibition of T-cell proliferation is related to prolonged T-cell survival. Oncogene 23 (2004) 3770-3780
81. Kip1. J Clin Invest 103 (1999) 597-604
82. Prasad R.C., Wang X.L., Law B.K., Davis B., Green G., Boone B., et al. Identification of genes, including the gene encoding p27Kip1, regulated by serine 276 phosphorylation of the p65 subunit of NF-κB. Cancer Lett 275 (2009) 139-149